Investigational drug · Phase 2
Dibotatug
Also called: DR-01
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Bone Marrow Failure Syndromes, Aplastic Anemias, Severe Aplastic Anemia (SAA).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "Dibotatug"
First trial start
2022
Jul 13, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Dibotatug", any sponsor or status.
Conditions studied
As listed on its trial records.
- Bone Marrow Failure Syndromes
- Aplastic Anemias
- Severe Aplastic Anemia (SAA)
- Severe Aplastic Anemia, Relapse
- Severe Aplastic Anemia, Refractory
- Non-severe Aplastic Anemia
- LGLL - Large Granular Lymphocytic Leukemia
- Primary Cutaneous Gamma-Delta T-Cell Lymphoma
- Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma
- Hepatosplenic T-cell Lymphoma
Approved drugs for the same conditions: Anemia · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Dibotatug" as an intervention, largest first.
Dren BioIndustry
NCT07712562 · 60 participants (planned) · Start Aug 14, 2026 · Primary completion Apr 2029
Drug: Dibotatug (DR-01) · For: Bone Marrow Failure Syndromes; Aplastic Anemias; Severe Aplastic Anemia (SAA) and 3 more
Sites: Duarte, California; Palo Alto, California; Miami, Florida · 10 sites in all
Dren BioIndustry
NCT07647627
Drug: Dibotatug
Newest research
PubMed records naming it or its code names, newest first.
- Anti-CD94 Monoclonal Antibody Dibotatug-Induced Response in a Refractory Primary CNS T-Cell Lymphoma.
Grommes C, Ting Z, Hong WJ, et al. · JCO Precis Oncol 2026
- SOHO State of the Art Updates and Next Questions | Beyond Romidepsin: Novel Therapeutic Targets and Emerging Strategies for Relapsed and Refractory Peripheral T-Cell Lymphoma.
Rana I, Zain J · Clin Lymphoma Myeloma Leuk 2026
- Allelic and haplotypic HLA analysis in patients with psoriatic arthritis: Low frequency of common alleles.
Calixto OJ, Meneses-Toro MA, Chacón PA, et al. · Biomedica 2024
- Role of HLA-DR Alleles to Increase Genetic Susceptibility to Onychomycosis in Nail Psoriasis.
Carrillo-Meléndrez H, Ortega-Hernández E, Granados J, et al. · Skin Appendage Disord 2016
- Relationship between HLA-DR gene polymorphisms and outcomes of hepatitis B viral infections: a meta-analysis.
Yan ZH, Fan Y, Wang XH, et al. · World J Gastroenterol 2012
- Role of major histocompatibility complex and ethnicity in acute renal graft rejection.
Torres-Machorro A, Camorlinga-Tagle N, Rodríguez-Ortiz C, et al. · Transplant Proc 2010
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.